

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and ~~cisplatin derivatives~~ can be used to reduce the growth of an ovarian tumor, comprising the steps of:
  - a) obtaining a sample of ovarian tumor cells;
  - b) determining whether the ovarian tumor cells express one or more sensitivity markers identified in Tables 1-6; and
  - c) identifying that paclitaxel and cisplatin ~~the agent~~ can be used to reduce the growth of the ovarian tumor cells when the one or more sensitivity markers are expressed.
2. **(Cancelled)** ~~The method of claim 1, wherein the agent is TAXOL, a TAXOL mimic, a TAXOL analog, or a TAXOL derivative.~~
3. **(Cancelled)** ~~The method of claim 1, wherein the agent is cisplatin, a cisplatin mimic, a cisplatin analog, or a cisplatin derivative.~~
4. **(Cancelled)** ~~The method of claim 1, wherein the agent is a combination of two or more agents consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives.~~
5. **(Currently Amended)** The method of claim 70, wherein expression is determined by detecting the amount of an mRNA transcript of SEQ ID NO:16 ~~mRNA~~ present in the sample.
6. **(Cancelled)** ~~The method of claim 70, wherein expression is determined by detecting the amount of protein that is encoded by SEQ ID NO:16 present in the sample.~~

7. **(Previously Presented)** The method of claim 1, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

8. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and cisplatin derivatives cannot be used to reduce the growth of an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;
- b) determining whether the ovarian tumor cells express one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1-6; and
- c) identifying that paclitaxel and cisplatin ~~the agent~~ cannot be used to reduce the growth of the ovarian tumor when one or more of the sensitivity markers in Tables 1-6 is not expressed ~~or is underexpressed~~ by the ovarian tumor cells.

9. **(Cancelled)** ~~The method of claim 8, wherein the agent is TAXOL, a TAXOL mimic, a TAXOL analog, or a TAXOL derivative.~~

10. **(Cancelled)** ~~The method of claim 8, wherein the agent cisplatin, a cisplatin mimic, a cisplatin analog, or a cisplatin derivative.~~

11. **(Cancelled)** ~~The method of claim 8, wherein the agent is a combination of two or more agents consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs and cisplatin derivatives.~~

12. **(Currently Amended)** The method of claim 71, wherein expression is determined by detecting the amount of an mRNA transcript of SEQ ID NO:16 ~~mRNA~~ present in the sample.

13. **(Cancelled)** ~~The method of claim 71, wherein expression is determined by detecting the amount of protein that is encoded by SEQ ID NO:16 present in the sample.~~

14. **(Previously Presented)** The method of claim 8, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

15-69. **(Cancelled)**

70. **(Previously Presented)** The method of claim 1, wherein the sensitivity marker is the marker of SEQ ID NO:16.

71. **(Previously Presented)** The method of claim 8, wherein the sensitivity marker is the marker of SEQ ID NO:16.